Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
Dimdazenil
Dimdazenil, sold under the brand name Junoenil, is a medication used in the treatment of insomnia in China. It is a benzodiazepine derivative and a partial positive allosteric modulator of the GABAA receptor with two- to four-fold higher functional affinity for the α1 subunit relative to the α2, α3, and α5 subunits.
Dimdazenil shows effectiveness in the treatment of insomnia, but has less intrinsic activity in comparison to currently-marketed benzodiazepines and the Z-drugs; however, it is thought that the lower efficacy may result in fewer side effects, such as motor incoordination. In China, dimdazenil is approved for short-term treatment of insomnia.
Dimdazenil was originally developed by Roche, based on preclinical data, as a non-sedating anxiolytic, but was found to produce sedation in humans in phase I clinical trials. For this reason, it was subsequently licensed to Evotec, which is now developing it for the treatment of insomnia. By 2007, dimdazenil completed phase II clinical trials for this indication, with positive findings reported. In China, the drug was developed by Zhejiang Jingxin Pharmaceutical.
Hub AI
Dimdazenil AI simulator
(@Dimdazenil_simulator)
Dimdazenil
Dimdazenil, sold under the brand name Junoenil, is a medication used in the treatment of insomnia in China. It is a benzodiazepine derivative and a partial positive allosteric modulator of the GABAA receptor with two- to four-fold higher functional affinity for the α1 subunit relative to the α2, α3, and α5 subunits.
Dimdazenil shows effectiveness in the treatment of insomnia, but has less intrinsic activity in comparison to currently-marketed benzodiazepines and the Z-drugs; however, it is thought that the lower efficacy may result in fewer side effects, such as motor incoordination. In China, dimdazenil is approved for short-term treatment of insomnia.
Dimdazenil was originally developed by Roche, based on preclinical data, as a non-sedating anxiolytic, but was found to produce sedation in humans in phase I clinical trials. For this reason, it was subsequently licensed to Evotec, which is now developing it for the treatment of insomnia. By 2007, dimdazenil completed phase II clinical trials for this indication, with positive findings reported. In China, the drug was developed by Zhejiang Jingxin Pharmaceutical.